| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 500mg | |||
| Other Sizes |
Purity: =99.78%
| Targets |
Ononin targets multiple signaling pathways including ERK/JNK/p38, PI3K/Akt/mTOR, NF-κB, and MAPK. It regulates apoptosis through these pathways. Ononin inhibits LPS-induced production of nitrite, prostaglandin E2, and pro-inflammatory cytokines IL-1β, IL-6, and TNF-α in RAW 264.7 macrophages. The compound may act by inducing erythropoietin expression. It also inhibits biofilm formation of Candida albicans. Ononin has anti-inflammatory and neuroprotective activities.
|
|---|---|
| ln Vitro |
In vitro, Ononin (10-100 µM, 24 h) shows anticancer activity against laryngeal cancer Hep-2 cells via inhibition of the ERK/JNK/p38 signaling pathway. Ononin (6.25-100 µM, 48 h) shows anticancer activity against human HepG2 cells with an IC50 of 40.8 µM. Ononin (3-10 µM) exerts antitumor effects against lung cancer cells A549 and HCC827 by regulating apoptosis through inhibiting the PI3K/Akt/mTOR pathway. Ononin (5 µM) inhibits LPS-induced production of nitrite, PGE2, and pro-inflammatory cytokines IL-1β, IL-6, and TNF-α by RAW 264.7 macrophages.
|
| ln Vivo |
In vivo, Ononin (30 mg/kg, oral administration, 12 days) shows neuroprotective effects against aluminium chloride-induced Alzheimer’s disease in rats. Ononin (10-50 mg/kg, oral, once daily for 60 days) mitigates streptozotocin-induced diabetic nephropathy in rats via alleviating oxidative stress and inflammatory markers. Ononin (30-60 mg/kg/day, gavage, 8 weeks) alleviates endoplasmic reticulum stress in doxorubicin-induced cardiotoxicity in rats by activating SIRT3. These in vivo studies confirm the compound’s oral activity and therapeutic potential.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Ononin involve measuring inhibition of signaling pathway components. ERK/JNK/p38 and PI3K/Akt/mTOR pathway inhibition is assessed using kinase activity assays or Western blot analysis of phosphorylated proteins in cell lysates. NF-κB activation is evaluated by measuring nuclear translocation or DNA binding activity. COX-2 enzyme activity may be assessed by measuring PGE2 production. Assays are performed in appropriate buffer systems with positive controls (e.g., specific pathway inhibitors). IC50 values for enzyme inhibition are calculated from dose-response curves.
|
| Cell Assay |
In vitro cell-based assays for Ononin are conducted in various cancer and immune cell lines. Hep-2 laryngeal cancer cells, HepG2 hepatocellular carcinoma cells, and A549/HCC827 lung cancer cells are cultured in appropriate media at 37°C with 5% CO2. Cells are treated with Ononin at varying concentrations (e.g., 3-100 µM) for 24-48 hours. Cell viability is assessed by MTT or CCK-8 assays. Apoptosis is evaluated by Annexin V/PI staining and caspase activity assays. Pathway protein phosphorylation is analyzed by Western blot. RAW 264.7 macrophages are used for anti-inflammatory assays with LPS stimulation. Experiments are performed in triplicate with appropriate controls.
|
| Animal Protocol |
In vivo animal studies for Ononin are conducted in rat models. For neuroprotection, aluminium chloride-induced Alzheimer’s disease model in rats is used, with Ononin administered orally at 30 mg/kg for 12 days. For diabetic nephropathy, streptozotocin-induced diabetic rats are treated with Ononin (10-50 mg/kg, oral, once daily for 60 days). For cardiotoxicity, doxorubicin-induced cardiotoxicity in rats is evaluated with Ononin (30-60 mg/kg/day, gavage, 8 weeks). Animals are monitored for clinical signs. Tissues and blood samples are collected for histopathological, biochemical, and biomarker analysis at study endpoints.
|
| ADME/Pharmacokinetics |
Ononin (MW 430.4 g/mol, C22H22O9) is an orally active isoflavone with favorable drug-like properties. The compound shows good oral bioavailability as demonstrated by its efficacy in oral administration studies. Ononin is metabolized to active metabolites that contribute to its pharmacological effects. The compound is distributed to tissues including brain, kidney, and heart, as evidenced by its effects in these organs. Pharmacokinetic parameters such as Cmax, Tmax, and half-life would be determined in species-specific studies. The compound shows stability under recommended storage conditions.
|
| Toxicity/Toxicokinetics |
Ononin is generally well-tolerated in preclinical studies at therapeutic doses. The compound has been evaluated in various animal models for its neuroprotective, anti-tumor, anti-diabetic, and cardio-protective effects. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| Additional Infomation |
Ononin is a 4'-methoxyisoflavone composed of Ononin linked to a β-D-pyranose group at the 7-position via a glycosidic bond. It is a plant metabolite. It is a monosaccharide derivative belonging to the 4'-methoxyisoflavones and 7-hydroxyisoflavones 7-O-β-D-glucoside class of compounds. Its function is related to Ononin. Ononin has been reported in Daphnia pulex, Astragalus hoantchy, and other organisms with relevant data. See also: Root (part) of the closely related Astragalus propinquus.
Ononin is an orally active isoflavone found in soybean, kudzu, and Radix astragali. It inhibits the ERK/JNK/p38 and PI3K/Akt/mTOR pathways and regulates apoptosis. Ononin has anti-tumor effects on laryngeal cancer and lung cancer. It exhibits neuroprotective effects, alleviates endoplasmic reticulum stress, and mitigates diabetic nephropathy. The compound has anti-inflammatory activity by inhibiting the NF-κB and MAPK pathways. Ononin also inhibits biofilm formation of Candida albicans. All applications are limited to non-human research use. |
| Molecular Formula |
C22H22O9
|
|---|---|
| Molecular Weight |
430.4047
|
| Exact Mass |
430.126
|
| Elemental Analysis |
C, 61.39; H, 5.15; O, 33.45
|
| CAS # |
486-62-4
|
| PubChem CID |
442813
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
697.8±55.0 °C at 760 mmHg
|
| Melting Point |
216ºC
|
| Flash Point |
245.7±25.0 °C
|
| Vapour Pressure |
0.0±2.3 mmHg at 25°C
|
| Index of Refraction |
1.655
|
| LogP |
0.63
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
31
|
| Complexity |
659
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
O1[C@@]([H])([C@@]([H])([C@@]([H])([C@@]([H])([C@@]1([H])C([H])([H])O[H])O[H])O[H])O[H])OC1C([H])=C([H])C2C(C(C3C([H])=C([H])C(=C([H])C=3[H])OC([H])([H])[H])=C([H])OC=2C=1[H])=O
|
| InChi Key |
MGJLSBDCWOSMHL-MIUGBVLSSA-N
|
| InChi Code |
InChI=1S/C22H22O9/c1-28-12-4-2-11(3-5-12)15-10-29-16-8-13(6-7-14(16)18(15)24)30-22-21(27)20(26)19(25)17(9-23)31-22/h2-8,10,17,19-23,25-27H,9H2,1H3/t17-,19-,20+,21-,22-/m1/s1
|
| Chemical Name |
3-(4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
|
| Synonyms |
Ononin; Formononetin Glucoside; Formononetin 7-O-Glucoside; Formononetin 7-O-β-D-Glucopyranoside
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~232.34 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.83 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.83 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.83 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3234 mL | 11.6171 mL | 23.2342 mL | |
| 5 mM | 0.4647 mL | 2.3234 mL | 4.6468 mL | |
| 10 mM | 0.2323 mL | 1.1617 mL | 2.3234 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA